LIXTE Biotechnology Holdings, Inc. is underwriting the first Good Health: Mind, Body & Soul Summit on February 19 at Morehouse College in Atlanta. As the exclusive pharmaceutical sponsor, LIXTE will showcase its lead oncology compound LB-100 alongside LIORA’s proton therapy technologies to an invitation-only audience of 150 health experts, artists and community advocates. The event—developed in partnership with De La Soul and Blacksmith Holdings—will highlight LIXTE’s commitment to health equity for Black men and families, positioning the company as a cultural as well as scientific leader. By linking its clinical-stage pipeline to broader conversations on cancer, heart disease and mental health, LIXTE aims to deepen stakeholder relationships and reinforce its brand among patient communities and institutional investors focused on social impact.

From January 28–29 at The Borgata in Atlantic City, LIXTE’s CEO Geordan Pursglove will conduct scheduled one-on-one meetings with hedge funds and biotech analysts at the DealFlow Discovery Conference. The company will present updated safety and preliminary efficacy data from phase 1 trials of LB-100 in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. LIXTE’s latest slides report that 80% of patients tolerated LB-100 at dose levels associated with anti-tumor activity and that combination studies with standard chemotherapies are on track for mid-2026 initiation. Pursglove is also set to outline LIXTE’s LiGHT System proton therapy pilot, designed to leverage its European research subsidiary’s proprietary technology, aiming to attract strategic partnerships and late-stage investors ahead of potential registration trials.